GoodRx, a company in the Medical Services industry, underperformed the S&P 500 this year.
2 reports, 2 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GoodRx, a company in the Medical Services industry, underperformed the S&P 500 this year.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.GoodRx underperformed the S&P 500 this year while operating in the Medical Services industry.1 source
GoodRx received analyst estimates and brokerage recommendations.1 source
Keep exploring
The entities involved
-
GoodRx
American prescription drug price tracking website and app
Nothing else this week.
Related events
- GoodRx CEO addressed the company's underperformance on August 13, 2025, as Rite Aid bankruptcy caused stores to be removed from networks. Inquiries focused on pharma manufacturer solutions growth.
- GoodRx stock traded on Nasdaq on August 1, 2026, while also being required to file sales disclosures with the SEC and holding a significant stake.
Coverage
Newest first; wire copies grouped- ZacksGoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per
- GuruFocus.comWhat To Expect From GoodRx Holdings Inc (GDRX) Q2 2025 Earnings GoodRx Holdings Inc (NASDAQ:GDRX) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue is